Combination therapy to treat erythropoietin-resistant anemia in chronic kidney disease
AssigneeThe Chinese University of Hong Kong
InventorsXiaoyu Yan, Raymond S.M Wong, Xiaoqing Fan, Huixi Zou
Life of this patent
Estimating the term…
Abstract
The subject invention pertains to novel methods of treatment for subjects suffering from anemia, particularly as a result of erythropoiesis-stimulating agents (ESAs) resistant anemia. The methods comprise administering at least two compositions to a subject, in which the compositions can comprise a first composition comprising an ESA and a second composition comprising a thrombopoietin receptor agonist (TPO-RA). The combination of ESA with TPO-RA can stimulate the expansion of hematopoietic stem cells.
Claims13
A method of treating erythropoiesis-stimulating agents resistant anemia in a subject comprising administering effective amounts of a first composition comprising an erythropoiesis-stimulating agent (ESA) and a second composition comprising a thrombopoietin receptor agonist (TPO-RA), wherein a dose of the ESA administered to the subject is about 0.01 mcg/kg to about 5 mcg/kg.
Dependencies are inferred from the claim text.